Clinical trial NCT02580708: Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
Official title: A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Non-small Cell Lung Cancer
Lead sponsor: Clovis Oncology, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Novartis Pharmaceuticals
First posted: 2015-10-20
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Detailed description: This is a Phase 1/2, open-label, non randomized, multicenter study evaluating the safety and efficacy of rociletinib administered in combination with trametinib.

This study will be conducted in 2 phases:

Phase 1: This will be the dose escalation phase of the study. Phase 1 will determine the MAD or MTD and RP2D of the combination of rociletinib and trametinib, and evaluate its safety and tolerability and PK profile in EGFRm NSCLC patients who have failed at least one prior EGFR TKI.

Phase 2: This will be the dose expansion phase. Phase 2 will evaluate the preliminary efficacy and pharmacodynamics of the combination of rociletinib and trametinib at the RP2D in two subsets of EGFRm NSCLC patients.

Eligibility criteria: Inclusion Criteria:

* Written informed consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study-specific evaluation
* Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion); measurable disease per RECIST 1.1
* Prior treatment with an EGFR TKI; in Phase 2, prior treatment with a T790M-directed EGFR TKI for patients in Group B. Previous chemotherapy is allowed; in Phase 2, immediate prior therapy must be EGFR TKI
* Patient willingness to undergo tumor biopsy at baseline and on treatment (optional for Phase 1; mandatory for Phase 2)
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy at least 3 months
* Adequate hematological and biological function; LVEF ≥50%

Exclusion Criteria:

* Documented evidence in tumor of exon 20 insertion, small cell transformation, or MET amplification
* Leptomeningeal carcinomatosis or other untreated or symptomatic CNS metastases (asymptomatic CNS metastases allowed if clinically stable without requirement for steroids within 2 weeks)
* Known preexisting interstitial lung disease or pneumonitis
* Concurrent use of QT-prolonging medication
* Uncontrolled diabetes (HA1C \> 10%) despite optional therapy
* Cardiac abnormalities:

  * Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia's method (QTcF) \>450 ms
  * Inability to measure QT interval on ECG
  * Personal or family history of long QT syndrome
  * Implantable pacemaker or implantable cardioverter defibrillator
  * Resting bradycardia \< 55 beats/min
* Inability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatment
* Presence of serious or unstable concomitant systemic disorder incompatible with the clinical study (eg, substance abuse; uncontrolled intercurrent illness including active infection; arterial thrombosis; unstable respiratory, hepatic, renal or cardiac disease; and other active malignancy)
* Pregnant or breastfeeding females and male or female patients who refuse to use adequate contraception during the study and for 16 weeks after the last dose of study treatment
* Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients

Primary outcomes:
measure: Incidence of treatment-emergent adverse events
timeFrame: Continuously, up to approximately 24 months
measure: Objective Response Rate (ORR)
timeFrame: Every 6 weeks until disease progression, up to approximately 24 months
measure: Cmax of rociletinib and trametinib at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: Tmax of rociletinib and trametinib at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: AUC of rociletinib and trametinib at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: Cmin of rociletinib and trametinib at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: t1/2 of rociletinib at steady state
timeFrame: Cycle 2 Day 1 to Day 2
Secondary outcomes:
measure: Duration of Response (DR) According to RECIST Version 1.1
timeFrame: Every 6 weeks until disease progression, up to approximately 24 months
measure: Disease Control Rate (DCR) According to RECIST Version 1.1
timeFrame: Every 6 weeks until disease progression, up to approximately 24 months
measure: Progression Free Survival (PFS) According to RECIST Version 1.1
timeFrame: Every 6 weeks until disease progression, up to approximately 24 months
measure: Overall Survival (OS)
timeFrame: Every 12 weeks until date of death, up to approximately 60 months
measure: Longitudinal changes in blood based biomarkers (i.e. mutations in EGFR) in ctDNA
timeFrame: Biomarker samples will be collected from each subject approximately every 3 weeks, up to approximately 24 months
measure: Cmax of rociletinib metabolites at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: Tmax of rociletinib metabolites at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: AUC of rociletinib metabolites at steady state
timeFrame: Cycle 2 Day 1 to Day 2
measure: Cmin of rociletinib metabolites at steady state
timeFrame: Cycle 2 Day 1 to Day 2
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: Charlotte
country: United States
facility: Levine Cancer Institute
state: North Carolina
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC - The Sarah Cannon Research Institute
state: Tennessee
city: Fairfax
country: United States
facility: Virginia Cancer Specialists
state: Virginia
Study officials:
affiliation: Clovis Oncology, Inc.
name: Paula O'Connor, MD
role: STUDY_DIRECTOR
References: